JP2024540445A - 複素環式ｎｌｒｐ３阻害剤 - Google Patents

複素環式ｎｌｒｐ３阻害剤 Download PDF

Info

Publication number
JP2024540445A
JP2024540445A JP2024528510A JP2024528510A JP2024540445A JP 2024540445 A JP2024540445 A JP 2024540445A JP 2024528510 A JP2024528510 A JP 2024528510A JP 2024528510 A JP2024528510 A JP 2024528510A JP 2024540445 A JP2024540445 A JP 2024540445A
Authority
JP
Japan
Prior art keywords
ethyl
pyridazin
methyl
substituted
piperidyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2024528510A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024540445A5 (OSRAM
Inventor
エイトケン，ルイス・スコット
ブッシュ，レア・オレリー
グーバ，ヴォルフガング
ヤーシュケ，ゲオルク
メッシュ，ステファニー・カタリナ
シュタイナー，サンドラ
トストルフ，アンドレアス・ミヒャル
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
F Hoffmann La Roche AG
Original Assignee
F Hoffmann La Roche AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by F Hoffmann La Roche AG filed Critical F Hoffmann La Roche AG
Publication of JP2024540445A publication Critical patent/JP2024540445A/ja
Publication of JP2024540445A5 publication Critical patent/JP2024540445A5/ja
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/5025—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • C07D491/048—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being five-membered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Pulmonology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
JP2024528510A 2021-11-17 2022-11-15 複素環式ｎｌｒｐ３阻害剤 Pending JP2024540445A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP21208773 2021-11-17
EP21208773.8 2021-11-17
PCT/EP2022/081866 WO2023088856A1 (en) 2021-11-17 2022-11-15 Heterocyclic nlrp3 inhibitors

Publications (2)

Publication Number Publication Date
JP2024540445A true JP2024540445A (ja) 2024-10-31
JP2024540445A5 JP2024540445A5 (OSRAM) 2025-10-24

Family

ID=78676487

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2024528510A Pending JP2024540445A (ja) 2021-11-17 2022-11-15 複素環式ｎｌｒｐ３阻害剤

Country Status (7)

Country Link
US (1) US20240409553A1 (OSRAM)
EP (1) EP4433480A1 (OSRAM)
JP (1) JP2024540445A (OSRAM)
CN (1) CN118234730A (OSRAM)
AR (1) AR127705A1 (OSRAM)
TW (1) TW202334153A (OSRAM)
WO (1) WO2023088856A1 (OSRAM)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11618751B1 (en) 2022-03-25 2023-04-04 Ventus Therapeutics U.S., Inc. Pyrido-[3,4-d]pyridazine amine derivatives useful as NLRP3 derivatives
US11319319B1 (en) 2021-04-07 2022-05-03 Ventus Therapeutics U.S., Inc. Compounds for inhibiting NLRP3 and uses thereof
US20240391881A1 (en) * 2021-09-30 2024-11-28 Origiant Pharmaceutical Co., Ltd. Pharmaceutical use and preparation method for substituted heteroaryl phthalazine derivative
US20260015357A1 (en) * 2022-07-01 2026-01-15 Neumora Therapeutics, Inc. Modulators of nlrp3 inflammasome and related products and methods
CN116789674B (zh) * 2022-08-24 2024-05-24 杭州高光制药有限公司 Nlrp3炎性小体抑制剂
US12331048B2 (en) 2022-10-31 2025-06-17 Ventus Therapeutics U.S., Inc. Pyrido-[3,4-d]pyridazine amine derivatives useful as NLRP3 inhibitors
CN121045190A (zh) * 2022-11-04 2025-12-02 药捷安康(南京)科技股份有限公司 Nlrp3炎症小体抑制剂及其应用
EP4644392A1 (en) * 2022-12-27 2025-11-05 Chia Tai Tianqing Pharmaceutical Group Co., Ltd. Pyridazine fused aryl ring compound and use thereof
WO2025026252A1 (en) * 2023-08-02 2025-02-06 Hangzhou Highlightll Pharmaceutical Co., Ltd Nlrp3 inflammasome inhibitors
WO2025133307A1 (en) * 2023-12-22 2025-06-26 Ac Immune Sa Heterocyclic modulators of the nlrp3 inflammasome pathway
WO2025153532A1 (en) 2024-01-16 2025-07-24 NodThera Limited Nlrp3 inhibitors and glp-1 agonists combination therapies
WO2025153624A1 (en) * 2024-01-17 2025-07-24 Ac Immune Sa Imidazo[1,2-d][1,2,4]triazine derivatives for use as inhibitors of the nlrp3 inflammasome pathway
WO2025153625A1 (en) * 2024-01-17 2025-07-24 Ac Immune Sa Imidazo[1,2-d][1,2,4]triazine derivatives for use as inhibitors of the nlrp3 inflammasome pathway
WO2026057747A1 (en) 2024-09-11 2026-03-19 Ac Immune Sa Therapeutic use of nlrp3 inflammasome pathway inhibitor compounds

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2868780B1 (fr) * 2004-04-13 2008-10-17 Sanofi Synthelabo Derives de la 1-amino-phthalazine, leur preparation et leur application en therapeutique
WO2018221433A1 (ja) * 2017-05-29 2018-12-06 第一三共株式会社 ヘテロアリールアミン誘導体
UY38687A (es) * 2019-05-17 2023-05-15 Novartis Ag Inhibidores del inflamasoma nlrp3, composiciones, combinaciones de los mismos y métodos para su uso
JP7843705B2 (ja) 2020-01-22 2026-04-10 エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト Ｎｌｒｐ３モジュレーターとしてのスルホンイミドアミド化合物
US20240327413A1 (en) 2021-06-29 2024-10-03 Zomagen Biosciences Ltd Nlrp3 modulators
TW202319055A (zh) 2021-07-21 2023-05-16 日商安斯泰來製藥股份有限公司 縮環噠嗪（ｐｙｒｉｄａｚｉｎｅ）化合物
PE20241727A1 (es) 2021-08-25 2024-08-19 Ptc Therapeutics Inc Inhibidores de nlrp3
US20240391881A1 (en) 2021-09-30 2024-11-28 Origiant Pharmaceutical Co., Ltd. Pharmaceutical use and preparation method for substituted heteroaryl phthalazine derivative
WO2023066377A1 (zh) 2021-10-22 2023-04-27 索智生物科技（浙江）有限公司 一种含氮化合物、其制备方法及应用

Also Published As

Publication number Publication date
CN118234730A (zh) 2024-06-21
EP4433480A1 (en) 2024-09-25
TW202334153A (zh) 2023-09-01
WO2023088856A1 (en) 2023-05-25
AR127705A1 (es) 2024-02-21
US20240409553A1 (en) 2024-12-12

Similar Documents

Publication Publication Date Title
US20240409553A1 (en) Heterocyclic nlrp3 inhibitors
JP7705963B2 (ja) トリアジン誘導体およびがんの処置におけるその使用
JP2024517917A (ja) Ｎｌｒｐ３阻害剤
US20240308977A1 (en) Pyridazine derivatives as inhibitors of nlrp3
JP2025540258A (ja) Ｎｌｒｐ３の阻害剤
JP2025537238A (ja) Ｎｌｒｐ３阻害剤としてのトリアジノン誘導体
JP2025539252A (ja) Ｎｌｒｐ３阻害剤としてのトリアジノン誘導体
JP2025519226A (ja) 新規化合物
JP2025537237A (ja) Ｎｌｒｐ３阻害剤としてのトリアジノン誘導体
CA2930754A1 (en) Pyrazolopyridine derivatives as modulators of tnf activity
US20260092076A1 (en) Novel compounds
RU2861618C2 (ru) Триазиновые производные и их применение в лечении рака
HK40111084A (zh) 杂环nlrp3抑制剂
WO2024218188A1 (en) 5-[5-(2-hydroxyphenyl)oxazolo[4,5-b]pyridin-2-yl]piperidin-2-one derivatives as nlpr3 inhibitors for the treatment of inflammatory diseases
EA052779B1 (ru) Триазиновые производные и их применение в лечении рака
CN121586712A (zh) 新颖化合物

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20251016

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20251016